Spegra Tablet 90N

About Spegra Tablet 90N

Spegra Tablet 90N is an advanced antiretroviral therapy designed to combat Human Immunodeficiency Virus (HIV) type-1, featuring a powerful combination of dolutegravir, emtricitabine, and tenofovir alafenamide. This medication is intended for use in adults and adolescents aged 12 years and older who weigh at least 40 kg, providing a crucial tool in managing HIV infections effectively. By targeting and inhibiting the replication of the virus, Spegra Tablet helps control viral load, thereby reducing the risk of progression to acquired immunodeficiency syndrome (AIDS). It is essential to adhere to prescribed dosages, as improper use can lead to drug resistance and treatment failure. Patients should be aware of potential side effects, which may include gastrointestinal disturbances and fatigue, and should discuss any concerns with their healthcare provider. Regular monitoring and follow-ups are critical to ensure optimal treatment outcomes and overall health. With its convenient formulation, Spegra Tablet 90N represents a significant step forward in HIV management, promoting a better quality of life for those affected by this virus.